Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 211
Filter
1.
Int J Food Sci Nutr ; 74(2): 279-290, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36843327

ABSTRACT

Vitamin D intakes are concerningly low. Food-based strategies are urgently warranted to increase vitamin D intakes and subsequently improve 25-hydroxyvitamin D (25(OH)D) concentrations. This acute randomised three-way crossover study investigated the efficacy of vitamin D biofortified pork derived from pigs exposed to UVB light to increase serum 25(OH)D3 concentrations, compared to a dose-matched vitamin D3 supplement and control pork in adults (n = 14). Blood samples were obtained at baseline and then 1.5, 3, 6, 9 and 24 h postprandially. There was a significant effect of time (p < 0.01) and a significant treatment*time interaction (p < 0.05). UV pork and supplement significantly increased within-group serum 25(OH)D3 concentrations over timepoints (p < 0.05) (max. change 0.9 nmol/L (2.2%) UV pork, 1.5 nmol/L (3.5%) supplement, 0.7 nmol/L (1.9%) control). Vitamin D biofortified pork modestly increased 25(OH)D3 concentrations and produced a similar response pattern as a dose-matched vitamin D supplement, but biofortification protocols should be further optimised to ensure differentiation from standard pork.


Subject(s)
Pork Meat , Red Meat , Vitamin D Deficiency , Humans , Adult , Animals , Swine , Cross-Over Studies , Biological Availability , Vitamin D , Vitamins , Cholecalciferol , Dietary Supplements
2.
Eur Rev Med Pharmacol Sci ; 27(2): 443, 2023 Jan.
Article in English | MEDLINE | ID: mdl-36734699

ABSTRACT

Correction to: European Review for Medical and Pharmacological Sciences 2022; 26 (22): 8713-8718. DOI: 10.26355/eurrev_202212_30543- PMID: 36524490-published online on December 15, 2022. After publication, the authors applied a correction to the funding statement: The authors extend their appreciation to the deputyship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number (lFP-2020-36). There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/30543.

3.
Eur Rev Med Pharmacol Sci ; 26(23): 8713-8718, 2022 12.
Article in English | MEDLINE | ID: mdl-36524490

ABSTRACT

OBJECTIVE: The ensuing ischemia due to the disruption of blood supply to the brain is one of the most common causes of stroke. Evidence suggests a clear association of the ischemic injury with vascular dementia and Alzheimer's disease (AD). In response to the brain ischemia, a cascade reaction starts leading to neuronal damage due to oxidative stress and other inflammatory mediators. A pilot study was done, which showed that following stroke, monomeric-C-reactive protein (mCRP) is expressed in large quantities around the infarcted zone and this CRP is able to induce neurodegeneration and inflammation potentially perpetuating dementia. MATERIALS AND METHODS: We examined both patient brain samples and excised mouse brain tissue, previously injected with 1.75 mg/mL mCRP into the CA1 area of the hippocampus through the stereotactic surgical procedures and followed them over a period of over 6 months. The distribution of mCRP was examined through immunohistochemistry (mouse anti-human mCRP-specific antibodies 8C10). RESULTS: We observed a novel finding: those micro vessels close to the injection location were strongly stained with mCRP only in the mice that had been injected with mCRP, indicating that this small blood vessel can spread it throughout the brain. CONCLUSIONS: mCRP found in the brain after a hemorrhagic stroke promotes damage over a large area via the induction of inflammation and degeneration of perivascular compartments.


Subject(s)
Alzheimer Disease , Stroke , Animals , Mice , C-Reactive Protein/metabolism , Pilot Projects , Inflammation , Neurons/metabolism , Alzheimer Disease/metabolism
4.
Ir Med J ; 113(1): 4, 2020 01 16.
Article in English | MEDLINE | ID: mdl-32298558

ABSTRACT

Introduction Is Therapeutic Listening effective for children born preterm presenting with sensory dysregulation, attention and cognitive problems? Methods 22 children (BW<1500g) 3-4 years were enrolled in a single centre, prospective, assessor-blinded RTC. Outcome measures: Winnie-Dunn Sensory Profile; Peabody Developmental Motor Scales; Reynell Attention Scale; Preschool Language Scales - 3; RAPT; WPPSI - IV; Parent Review Questionnaires. Results The intervention group (n=9) showed better improvement in sensory processing, compared to controls (n=9) (6.4 fold improvement in sensation seeking; 5.0 in auditory processing; 4.0 in tactile processing). Six intervention children (67%) improved in vestibular processing. Attention levels improved for 9 (100%) children in the intervention group and for 7 (78%) in the control group. Higher level domains (Peabody motor skills, Auditory Comprehension, Expressive Communication, RAPT scale, and WPPSI scores) showed mixed results. Parents reported positive changes in their child's development. Conclusion Therapeutic Listening (TL) is a feasible intervention for preterm children to improve attention levels and sensory processing skills.


Subject(s)
Attention , Cognition Disorders/therapy , Sensation Disorders/therapy , Child, Preschool , Humans , Motor Skills , Prospective Studies
5.
Diabet Med ; 36(6): 761-770, 2019 06.
Article in English | MEDLINE | ID: mdl-30868654

ABSTRACT

AIM: To explore the organizational context in which Type 2 diabetes structured group education is provided. METHODS: Four Clinical Commissioning Groups in England providing Type 2 diabetes structured self-management education participated in a qualitative study exploring the context for provision of that education. Using UK National Diabetes Audit returns, two Clinical Commissioning Groups were selected that had non-attendance rates of ≤25%, and two that had non-attendance rates of ≥50%. Between May 2016 and August 2017, 20 interviews were conducted with Clinical Commissioning Group staff including: commissioners, healthcare professionals, managers, general practitioners and diabetes educators. Data gathering was prolonged as it proved challenging to engage with healthcare staff as a result of frequent local restructuring and service disruption. RESULTS: Local audits revealed discrepancies in basic data such as referral and attendance numbers compared with national audit data. There was a commonality in the themes identified from interviews: diabetes education was rarely embedded in service structure; where education uptake was poor, a lack of central support to delivery teams was noticeable; and where education uptake was positive, delivery teams were actively engaged, sometimes relying on enthusiastic individuals. Both situations put the local sustainability of diabetes education at risk. CONCLUSIONS: There appears to be a link between attendance rates and organizational issues, therefore, when considering how to increase attendance rates, the state of the diabetes education infrastructure should be reviewed. Good uptake of diabetes education can be too reliant on the enthusiastic commitment of small teams or individuals delivering the education.


Subject(s)
Diabetes Mellitus, Type 2/therapy , Patient Education as Topic/organization & administration , Self-Management/education , Attitude of Health Personnel , Clinical Audit , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/psychology , England/epidemiology , General Practitioners , Humans , Patient Acceptance of Health Care/psychology , Patient Acceptance of Health Care/statistics & numerical data , Patient Education as Topic/economics , Patient Participation/psychology , Patient Participation/statistics & numerical data , Professional-Patient Relations , Qualitative Research , Self Care/standards , Self Care/statistics & numerical data , Surveys and Questionnaires , Training Support
6.
Sci Rep ; 5: 13281, 2015 Sep 03.
Article in English | MEDLINE | ID: mdl-26335098

ABSTRACT

Alzheimer's disease (AD) increases dramatically in patients with ischaemic stroke. Monomeric C-reactive protein (mCRP) appears in the ECM of ischaemic tissue after stroke, associating with microvasculature, neurons and AD-plaques, Aß, also, being able to dissociate native-CRP into inflammatory, mCRP in vivo. Here, mCRP injected into the hippocampal region of mice was retained within the retrosplenial tract of the dorsal 3rd ventrical and surrounding major vessels. Mice developed behavioural/cognitive deficits within 1 month, concomitant with mCRP staining within abnormal looking neurons expressing p-tau and in beta-amyloid 1-42-plaque positive regions. mCRP co-localised with CD105 in microvessels suggesting angiogenesis. Phospho-arrays/Western blotting identified signalling activation in endothelial cells and neurons through p-IRS-1, p-Tau and p-ERK1/2-which was blocked following pre-incubation with mCRP-antibody. mCRP increased vascular monolayer permeability and gap junctions, increased NCAM expression and produced haemorrhagic angiogenesis in mouse matrigel implants. mCRP induced tau244-372 aggregation and assembly in vitro. IHC study of human AD/stroke patients revealed co-localization of mCRP with Aß plaques, tau-like fibrils and IRS-1/P-Tau positive neurons and high mCRP-levels spreading from infarcted core regions matched reduced expression of Aß/Tau. mCRP may be responsible for promoting dementia after ischaemia and mCRP clearance could inform therapeutic avenues to reduce the risk of future dementia.


Subject(s)
Alzheimer Disease/complications , Alzheimer Disease/metabolism , Brain Ischemia/complications , Brain Ischemia/metabolism , Neurons/metabolism , Receptors, Immunologic/metabolism , Animals , Biomarkers/metabolism , Disease Progression , Male , Mice , Mice, Inbred C57BL
7.
Ir Med J ; 107(6): 166-8, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24988830

ABSTRACT

The Bayley scale of infant development is employed as the performance indicator at 2 years corrected gestational age for high risk paediatric groups. We compare neurodevelopmental outcomes in two cohorts of VLBW infants born in 1999 to a cohort born a decade later, while also examining the challenges of direct comparison of modified scales: BSID-II (2nd edition of the scales) with Bayley-III, BSID-II was used in the 1999 group and Bayley-III for the 2009 cohort. We demonstrated that over a ten year period there was an improvement in neurodevelopmental scores achieved in VLBW babies. Overall there was almost an 8 point increase in the cognitive scores from the 2009 cohort compared with the 1999 cohort in this time period. The mean motor score increased by 6 points when comparing 1999 and 2009. However we highlight the difficulties in comparing developmental scales, and consider whether Bayley-III overestimates developmental ability?


Subject(s)
Child Development , Infant, Premature , Infant, Very Low Birth Weight , Child, Preschool , Cognition , Developmental Disabilities/diagnosis , Female , Humans , Infant, Newborn , Infant, Premature/growth & development , Infant, Premature/psychology , Infant, Very Low Birth Weight/growth & development , Infant, Very Low Birth Weight/psychology , Male , Motor Skills , Neuropsychological Tests , Retrospective Studies
8.
J Thromb Haemost ; 11(11): 2048-58, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24119011

ABSTRACT

BACKGROUND: Pentraxins are inflammatory mediators linked to cardiovascular disease; however, their role in thrombosis remains to be fully elucidated. AIMS: We investigated the role of pentraxins in thrombus formation on different vascular substrates under flow conditions. METHODS: Native C-reactive protein (nCRP) and serum amyloid P (SAP) effects on thrombosis were evaluated under flow conditions on substrates placed in flat perfusion chambers. nCRP and dissociated monomeric CRP (mCRP) distributions were visualized by use of confocal microscopy. The effects of nCRP on vascular substrates were tested in the Badimon chamber. RESULTS: mCRP, but not nCRP, induced a significant activation in platelet deposition, whereas SAP induced an activation only on fibrinogen-coated substrates. The effects of CRP on platelet deposition were significantly reduced by statin treatment. mCRP resulting from recirculation of blood containing nCRP over a thrombogenic vessel wall induced increased platelet deposition. Blocking glycoprotein IIb-IIIa prevented the effects of CRP dissociation and significantly reduced platelet deposition. Annexin V treatment did not block monomerization of CRP on activated platelets. CONCLUSIONS: Under flow conditions, platelet deposited on all tested biological substrates support nCRP dissociation into mCRP. The effect is dependent on the thrombogenic potency of the substrate to trigger initial platelet deposition. Exposure of glycoprotein IIb-IIIa in the platelet surface supports nCRP dissociation. CRP monomerization was not dependent on the aminophospholipid exposed on the surface of activated platelets. The dissociated mCRP is trapped in the growing platelet aggregate and stimulates further platelet deposition. SAP increases platelet deposition only on fibrin monolayers. Therefore, pentraxins induce a platelet activation effect linking inflammation and thrombosis.


Subject(s)
Blood Platelets/metabolism , C-Reactive Protein/metabolism , Nerve Tissue Proteins/metabolism , Platelet Glycoprotein GPIIb-IIIa Complex/metabolism , Annexin A5/metabolism , Cell Adhesion , Healthy Volunteers , Humans , Immunity, Innate , Inflammation , Phospholipids/metabolism , Platelet Activation , Platelet Adhesiveness , Protein Isoforms , Serum Amyloid P-Component/metabolism , Shear Strength , Simvastatin/pharmacology , Thrombosis/metabolism
9.
Cerebrovasc Dis ; 34(3): 240-5, 2012.
Article in English | MEDLINE | ID: mdl-23018289

ABSTRACT

BACKGROUND: At the present time, the determination of the outcome of stroke patients is based on the analysis of clinical and neuroimaging data. The use of prognostic blood biomarkers could aid in decision-making processes, e.g. admitting patients to specialized stroke units. Although the prognostic role of natriuretic peptides has been studied in heart failure and coronary diseases, the value of brain natriuretic peptide (BNP) is less known within the field of strokes. OBJECTIVE: We aimed to study the relationship between plasma levels of BNP and acute neurological worsening or mortality after stroke in a large cohort of patients (investigating both ischemic and hemorrhagic disease). METHODS: Consecutive stroke patients (ischemic and hemorrhagic) admitted to the Stroke Unit of our University Hospital within 24 h of the onset of symptoms were included. Stroke severity was assessed according to the National Institutes of Health Stroke Scale (NIHSS) at admission and at discharge. Neurological worsening was defined as an increase of 4 or more points in the NIHSS score or death during the patient's stay at the Stroke Unit. Blood samples were drawn upon admission to measure plasma levels of BNP (Biosite Inc., San Diego, Calif., USA). Statistical analysis was performed using SPSS 15.0 and R software. RESULTS: Altogether, 896 patients were included in the study. BNP plasma levels were higher among patients who deteriorated the most over time (n = 112; 90.5 vs. 61.2 ng/l; p = 0.006) or died (n = 83; 118.2 vs. 60.9 ng/l; p < 0.001). Multivariate logistic regression analysis indicated that plasma BNP level was an independent predictor of neurological worsening [BNP >56.7 ng/l; odds ratio (OR) = 1.64; p = 0.04] and death after stroke (BNP >65.3 ng/l; OR = 1.97; p = 0.034). Adding BNP level to other well-known clinical predictors of bad outcome did not significantly increase the predictive value. CONCLUSIONS: Plasma levels of BNP measured during the acute phase of stroke are associated both with early neurological worsening and mortality. However, this biological information does not supply prognostic information which would add to clinical variables, which limits its use as a biomarker. Further investigation and systematic reviews are needed to clarify the role of natriuretic peptides in stroke outcome.


Subject(s)
Disease Progression , Natriuretic Peptide, Brain/blood , Stroke/diagnosis , Stroke/mortality , Aged , Aged, 80 and over , Biomarkers/blood , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Prognosis , Prospective Studies , Retrospective Studies , Severity of Illness Index , Stroke/blood , Survival Rate
10.
Eur J Vasc Endovasc Surg ; 39(4): 388-95, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20122857

ABSTRACT

OBJECTIVE: A challenge facing clinicians is identifying patients with asymptomatic carotid disease at risk of plaque instability. We hypothesise that locally released angiogenic growth factors contribute to plaque instability. METHODS: Carotid endarterectomy specimens from eight symptomatic and eight asymptomatic patients were interrogated for microvessel density and angiogenic growth factor expression histologically using immunofluorescence, and biochemically using quantitative real-time polymerase chain reaction (q-RT-PCR). Bio-Plex suspension array was used to assess circulating biomarkers in venous blood from the same patients and six healthy age-matched controls. RESULTS: Immunofluorescence demonstrated significantly greater neovessel density in symptomatic plaques (P=0.010) with elevated expression of hepatocyte growth factor (HGF) (P=0.001) and its receptor MET (P=0.011) than in asymptomatic plaques. The q-RT-PCR demonstrated up-regulation of Endoglin (CD105), HGF (P=0.001) and MET (P=0.011) in the plaques of symptomatic versus asymptomatic patients. Bio-Plex suspension array demonstrated elevated HGF (P=0.002) serum levels in symptomatic versus asymptomatic patients and healthy controls, and decreased platelet-derived growth factor (PDGF) (P=0.036) serum levels in symptomatic versus asymptomatic patients. CONCLUSION: Plaque instability may be mediated by HGF-induced formation of new microvessels, and decreased vessel stability resulting from decreased PDGF. Suspension array technology has the potential to identify circulating biomarkers that correlate with plaque rupture risk.


Subject(s)
Angiogenic Proteins/analysis , Carotid Artery, Internal/chemistry , Carotid Artery, Internal/pathology , Carotid Stenosis/metabolism , Carotid Stenosis/pathology , Microvessels/pathology , Neovascularization, Pathologic/pathology , Stroke/etiology , Actins/analysis , Aged , Angiogenic Proteins/blood , Angiogenic Proteins/genetics , Antigens, CD/analysis , Biomarkers/blood , Carotid Stenosis/complications , Carotid Stenosis/surgery , Case-Control Studies , Disease Progression , Endarterectomy, Carotid , Endoglin , Female , Fluorescent Antibody Technique , Hepatocyte Growth Factor/analysis , Humans , Male , Microarray Analysis , Middle Aged , Platelet-Derived Growth Factor/analysis , Polymerase Chain Reaction , Predictive Value of Tests , Proto-Oncogene Proteins c-met/analysis , Receptors, Cell Surface/analysis , Receptors, Growth Factor/analysis , Risk Assessment , Rupture , Stroke/metabolism , Stroke/pathology
11.
Mol Biosyst ; 6(3): 444-50, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20174673

ABSTRACT

Activation of vasa vasorum (the microvessels supplying the major arteries) at specific sites in the adventitia initiates their proliferation or 'angiogenesis' concomitant with development of atherosclerotic plaques. Haemorrhagic, leaky blood vessels from unstable plaques proliferate abnormally, are of relatively large calibre but are immature neovessels poorly invested with smooth muscle cells and possess structural weaknesses which may contribute to instability of the plaque by facilitation of inflammatory cell infiltration and haemorrhagic complications. Weak neovascular beds in plaque intima as well as activated adventitial blood vessels are potential targets for molecular imaging and targeted drug therapy, however, the majority of tested, currently available imaging and therapeutic agents have been unsuccessful because of their limited capacity to reach and remain stably within the target tissue or cells in vivo. Nanoparticle technology together with magnetic resonance imaging has allowed the possibility of imaging of neovessels in coronary or carotid plaques, and infusion of nanoparticle suspensions using infusion catheters or implant-based drug delivery represents a novel and potentially much more efficient option for treatment. This review will describe the importance of angiogenesis in mediation of plaque growth and development of plaque instability and go on to investigate the possibility of future design of superparamagnetic/perfluorocarbon-derived nanoparticles for imaging of the vasculature in this disease or which could be directed to the adventitial vasa vasorum or indeed intimal microvessels and which can release active payloads directed against primary key external mitogens and intracellular signalling molecules in endothelial cells responsible for their activation with a view to inhibition of angiogenesis.


Subject(s)
Atherosclerosis/diagnosis , Atherosclerosis/drug therapy , Diagnostic Imaging/methods , Drug Delivery Systems/methods , Nanotechnology/methods , Animals , Atherosclerosis/pathology , Fibroblasts/metabolism , Humans , Metal Nanoparticles/administration & dosage , Metal Nanoparticles/chemistry , Models, Molecular
12.
Hippokratia ; 14(4): 291-3, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21311643

ABSTRACT

BACKGROUND: Oesophageal cancer with liver metastasis is rare and when diagnosed is usually advanced and surgical management is contraindicated.Method-Results: We report the case of a patient who presented with oesophageal cancer and liver metastasis. The patient received chemotherapy combined with RFA to liver tumour. Subsequently she was subjected to oesophagectomy and liver resection of segment 5 extended into segment 8. Patient underwent adjuvant chemotherapy post-operatively and remains disease-free until now, 29 months after operation. CONCLUSION: Oesophageal cancer with concomitant liver metastasis is a rare and lethal disease. Multimodal management including surgery may offer prolonged survival in highly selected patients.

13.
J Vasc Res ; 47(4): 323-35, 2010.
Article in English | MEDLINE | ID: mdl-20016206

ABSTRACT

BACKGROUND/AIMS: Angiogenesis is a feature of the atherogenic process, with intimal neovascularisation arising from vessels in the adventitia, adjacent to a plaque. Immature, leaky blood vessels from unstable plaques proliferate abnormally and, being poorly invested with smooth muscle cells, may contribute to instability of the plaque by facilitation of inflammatory cell infiltration and haemorrhagic complications. METHODS: We used laser-capture microdissection to isolate angiogenic areas of the extracellular matrix (containing CD105/flt-1-positive, fragile thin-walled vessels) and non-angiogenic vascular areas (CD105-negative, with smooth muscle cell covering) of complicated endarterectomy plaques, and specifically designed angiogenesis-TaqMan real-time PCR microarrays to identify gene expression. RESULTS: Important pro-angiogenic components, including Notch-3, delta-like-4 (DLL4), Tie-2, angiopoietin-1 (Angio-1) and receptor for advanced glycation end products (RAGE), and one anti-angiogenic factor, endostatin, were up-regulated in these regions. Immunohistochemistry demonstrated localisation within intimal, active (CD105-positive) microvessels and co-localisation of Notch-3 and DLL4/Tie-2 and Angio-1 in the same vessels indicating multiple/synergistic signalling mechanisms associated with vessel development. CONCLUSION: These data, although providing only a snapshot of information, demonstrate that plaque vascularisation occurs in the presence of multiple angiogenically active factors. Knowledge of their combined effects could help in the formulation of novel therapeutics designed to stabilise or prevent their formation in the treatment of atherosclerosis.


Subject(s)
Angiogenic Proteins/genetics , Carotid Stenosis/genetics , Dissection/instrumentation , Gene Expression Profiling/methods , Genetic Markers , Lasers , Neovascularization, Physiologic/genetics , Oligonucleotide Array Sequence Analysis , Polymerase Chain Reaction , Adaptor Proteins, Signal Transducing , Aged , Angiogenic Proteins/analysis , Angiopoietin-1/genetics , Antigens, CD/analysis , Calcium-Binding Proteins , Carotid Arteries/chemistry , Carotid Arteries/immunology , Carotid Arteries/surgery , Carotid Stenosis/immunology , Carotid Stenosis/physiopathology , Carotid Stenosis/surgery , Endarterectomy, Carotid , Endoglin , Endostatins/genetics , Humans , Immunohistochemistry , Intercellular Signaling Peptides and Proteins/genetics , Male , Middle Aged , Receptor for Advanced Glycation End Products , Receptor, Notch3 , Receptor, TIE-2/genetics , Receptors, Cell Surface/analysis , Receptors, Immunologic/genetics , Receptors, Notch/genetics , Rupture , Vascular Endothelial Growth Factor Receptor-1/genetics
14.
Int J Oncol ; 35(4): 761-73, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19724912

ABSTRACT

We used short-interfering RNA (siRNA) to knockdown the hyaluronan (HA) receptors CD44 and the receptor for hyaluronan-mediated motility (RHAMM) in vascular endothelial cells to investigate their role in angiogenesis. We showed that CD44 and RHAMM single knockdown inhibited low molecular weight hyaluronan (o-HA)-induced endothelial cell tube formation in Matrigel, but no change in the control, epidermal growth factor-induced tube formation was observed. Using a Kinexus phosphoprotein array and confirmational Western blotting we were able to show a differential effect on HA-induced protein expression after CD44 and RHAMM knockdown. CD44 knockdown abolished o-HA-induced membrane phospho-protein kinase C-alpha (PKC-alpha) and down-stream phospho-gamma-adducin expression. Using the PKC inhibitor Go6976, we demonstrated the involvement of PKC-alpha and gamma-adducin in o-HA-induced tube formation, whilst o-HA-induced enzymatic activity of MMP9 was also reduced. This suggests that endothelial tube formation involves activation of MMP9 via PKC-alpha. Furthermore, the involvement of gamma-adducin in o-HA-induced F-actin cytoskeleton rearrangement was CD44-dependent and the reduction of CD44 expression lead to a change in endothelial cell morphology. Both RHAMM and CD44 knockdown completely inhibited o-HA-induced Cdc2 (Cdk1) phosphorylation suggesting a possible involvement in cell cycle control. Although CD44 and RHAMM are both involved in o-HA-induced endothelial tube formation in Matrigel, they mediate distinct angiogenic signalling pathway and for the first time we demonstrated the specific involvement of gamma-adducin in CD44/o-HA-induced endothelial tube formation. The data presented here extend our understanding of key stages of the processes of o-HA-induced angiogenesis which may have relevance to tumour progression.


Subject(s)
CDC2 Protein Kinase/metabolism , Calmodulin-Binding Proteins/metabolism , Endothelial Cells/metabolism , Extracellular Matrix Proteins/metabolism , Hyaluronan Receptors/metabolism , Hyaluronic Acid/metabolism , Neovascularization, Physiologic , Oligosaccharides/metabolism , Signal Transduction , Actins/metabolism , Animals , Blotting, Western , Carbazoles/pharmacology , Cattle , Cell Shape/drug effects , Cells, Cultured , Endothelial Cells/drug effects , Endothelial Cells/immunology , Epidermal Growth Factor/metabolism , Extracellular Matrix Proteins/genetics , Fluorescent Antibody Technique , Hyaluronan Receptors/genetics , Hyaluronic Acid/analogs & derivatives , Matrix Metalloproteinase 9/metabolism , Neovascularization, Physiologic/drug effects , Phosphorylation , Protein Array Analysis , Protein Kinase C-alpha/antagonists & inhibitors , Protein Kinase C-alpha/metabolism , Protein Kinase Inhibitors/pharmacology , RNA Interference , RNA, Small Interfering/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects
15.
Histol Histopathol ; 24(11): 1473-8, 2009 11.
Article in English | MEDLINE | ID: mdl-19760596

ABSTRACT

Native CRP (nCRP) is a pentameric oligoprotein composed of identical 23 KDa subunits which can be irreversibly dissociated to form free subunits or monomeric CRP (mCRP). mCRP has a reduced aqueous solubility and a tendency to aggregate into matrix-like lattices in various tissues, in particular, blood vessel walls. A dramatic increase in expression of mCRP occurs in angiogenic blood vessels derived from stroked brain regions, atherosclerotic arteries and active vessels from other angiogenic diseases such as Alzheimer's. Furthermore, mCRP unlike the native molecule is highly angiogenic to vascular endothelial cells in vitro and therefore might impact on the processes of vascularization and re-modelling thus affecting tissue survival and development. In this mini-review, we will discuss the differences in the biological properties between nCRP and mCRP. We will provide a brief historical background to the importance of nCRP as a biomarker for cardiovascular disease. We will explain the mechanisms of conversion of nCRP to its monomeric form and describe evidence for the role of mCRP in modulation of endothelial cell activation, promotion of inflammatory status and thrombus formation in cardio/cerebrovascular disease. Finally, we will provide evidence for the accumulation of mCRP in angiogenic microvessels from diseased tissue, and demonstrate its highly pro-angiogenic capabilities. The discovery of the existence of this tissue-associated, highly angiogenic monomeric form of CRP capable of cellular binding and intra-cellular signal transduction activation may help in our understanding of the processes responsible for modulation of angiogenesis and inflammation in disease.


Subject(s)
C-Reactive Protein/metabolism , Cardiovascular Diseases/metabolism , Endothelial Cells/metabolism , Inflammation/metabolism , Neovascularization, Pathologic/metabolism , Thrombosis/metabolism , Animals , Biomarkers/analysis , Biomarkers/metabolism , C-Reactive Protein/immunology , Cardiovascular Diseases/immunology , Cerebrovascular Disorders/immunology , Cerebrovascular Disorders/metabolism , Endothelial Cells/immunology , Humans , Inflammation/immunology , Neovascularization, Pathologic/immunology , Signal Transduction/physiology , Thrombosis/immunology
16.
Pathobiology ; 76(3): 129-35, 2009 May.
Article in English | MEDLINE | ID: mdl-19468252

ABSTRACT

OBJECTIVES: Recovery from stroke is dependent on the survival of neurons in the dynamic peri-infarcted region. Although several markers of neuronal injury and apoptotic cell death have been described, administration of neuroprotective drugs directed at specific molecules has had limited success. A complete understanding of deregulated genes associated with neuronal death would be beneficial. Our previous microarray studies identified increased expression of a novel protein, the B-cell translocation gene 2 (BTG2), in infarcted regions. METHODS: We have used immunohistochemistry and Western blotting to examine the expression and localization of BTG2 in stroked brain tissue and immunofluorescent staining of human fetal brain neurons to determine if oxygen-glucose deprivation affected its expression. RESULTS: We show that BTG2 is strongly expressed in peri-infarcted and infarcted regions of brain tissue, localizing in neuronal nuclei and cytoplasm, whilst being absent or very weakly expressed in normal looking contralateral tissue. Exposure of human fetal brain neurons to oxygen-glucose deprivation also induced BTG2 expression in the cytoplasm and perinuclear regions of cells staining positive for propidium iodide (a marker of nuclear damage). CONCLUSIONS: BTG2 may be a modulator of cell survival and differentiation and could help to protect against cell death by inhibition of necrosis and/or apoptotic signalling pathways.


Subject(s)
Brain Ischemia/metabolism , Brain/metabolism , Immediate-Early Proteins/metabolism , Neurons/metabolism , Stroke/metabolism , Aged , Aged, 80 and over , Blotting, Western , Cells, Cultured , Female , Fetus , Fluorescent Antibody Technique , Genes, Tumor Suppressor , Humans , Immunohistochemistry , Male , Middle Aged , Tumor Suppressor Proteins
17.
J Asian Nat Prod Res ; 11(2): 159-67, 2009.
Article in English | MEDLINE | ID: mdl-19219729

ABSTRACT

We investigated the potential of symplocomoside (1) and symponoside (2), glycosides isolated from the bark of Symplocos racemosa to inhibit thymidine phosphorylase (TP) activity and associated angiogenesis. Compound 1 was a reversible, noncompetitive inhibitor of deoxythymidine binding to TP (IC(50) = 65.45 +/- 5.08 microM; K(i) = 62.83 +/- 2.10 microM) and 2 was a reversible, uncompetitive inhibitor (IC(50) = 94.17 +/- 4.05 microM; K(i) = 101.95 +/- 1.65 microM). Molecular modeling analysis indicated that both compounds bound at the active site of the enzyme but not solely to amino acid residues involved in catalysis. Both compounds were active in in vitro angiogenic assays inhibiting endothelial cell migration and invasion in Matrigel, but did not inhibit growth factor-induced proliferation and were not cytotoxic. Compound 1 may have potential as an anti-angiogenic and anti-tumor agent.


Subject(s)
Angiogenesis Inhibitors/isolation & purification , Angiogenesis Inhibitors/pharmacology , Glycosides/isolation & purification , Glycosides/pharmacology , Models, Molecular , Thymidine Phosphorylase/antagonists & inhibitors , Angiogenesis Inhibitors/chemistry , Benzimidazoles , Cyclopentanes , Drug Screening Assays, Antitumor , Glycosides/chemistry , Humans , Kinetics , Molecular Conformation , Molecular Structure , Plant Bark/chemistry
18.
Expert Opin Investig Drugs ; 17(9): 1301-14, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18694364

ABSTRACT

BACKGROUND: In this review we provide the reader with an analysis of the importance of VEGF in modulating the angiogenic process in vascular diseases. OBJECTIVES: We have described the key role of VEGF in the development of the major angiogenic diseases including ocular retinopathies, solid tumour growth and atherosclerotic plaque development. METHODS: Following a brief description of the disease, a detailed literature review of the mechanisms through which VEGF induces promotion of neovascularisation and current anti-VEGF therapies is provided for the reader. RESULTS/CONCLUSIONS: Current and future potential clinical therapies are discussed in particular concerning our thoughts on future directives involving adenoviral-mediated gene targeting, nanotechnology and combinational therapies.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Vascular Endothelial Growth Factors/antagonists & inhibitors , Angiogenesis Inhibitors/chemistry , Animals , Atherosclerosis/drug therapy , Atherosclerosis/metabolism , Eye Diseases/drug therapy , Eye Diseases/metabolism , Humans , Neoplasms/blood supply , Neoplasms/drug therapy , Neoplasms/metabolism , Neovascularization, Pathologic/drug therapy , Vascular Endothelial Growth Factors/metabolism
19.
Pathobiology ; 75(4): 209-25, 2008.
Article in English | MEDLINE | ID: mdl-18580067

ABSTRACT

Formation of unstable plaques frequently results in atherothrombosis, the major cause for ischaemic stroke, myocardial infarction and peripheral arterial disease. Patients who have symptomatic thrombosis in one vascular bed are at increased risk of disease in other beds. However, the development of the disease in carotid, coronary and peripheral arteries may have different pathophysiology suggesting that more complex treatment protocols may have to be designed to reduce plaque development at different locations. In this review we describe the known risk factors, compare the developmental features of coronary and carotid plaque development and determine their association with end-point ischaemic events. Differences are also seen in the genetic contribution to plaque development as well as in the deregulation of gene and protein expression and cellular signal transduction activity of active cells in regions susceptible to thrombosis. Differences between carotid and coronary artery plaque development might help to explain the differences in anatomopathological appearance and risk of rupture.


Subject(s)
Carotid Artery Diseases/pathology , Coronary Artery Disease/pathology , Adult , Aged , Aged, 80 and over , Carotid Artery Diseases/blood , Carotid Artery Diseases/genetics , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Coronary Artery Disease/blood , Coronary Artery Disease/genetics , Female , Humans , Male , Middle Aged , Rupture, Spontaneous , Tunica Intima/pathology
20.
Angiogenesis ; 11(3): 245-56, 2008.
Article in English | MEDLINE | ID: mdl-18330714

ABSTRACT

Angiogenesis, the growth of new blood vessels from the pre-existing vasculature is of physiological and pathological importance. We have investigated the anti-angiogenic potential of two naturally occurring sesterterpenes, leucosesterterpenone (compound 1) and leucosterlactone (compound 2) isolated from the Himalayan plant Leucosceptrum canum and identified as having biological activity in preliminary screening. Compound 1 inhibited fibroblast growth factor-2-induced proliferation, migration in a wounding assay, chemotaxis and tube formation with small vessel (human dermal) and large vessel (bovine aortic) endothelial cells while compound 2 was largely inactive. Both compounds were also active in an in vivo angiogenic model using the chick chorioallantoic membrane. Neither compounds showed inhibitory activity in the absence of fibroblast growth factor-2. We were able to demonstrate in a binding assay that compounds 1 and 2 bound to the fibroblast growth factor-2 receptor-1 with IC(50) values of 1.4 +/- 0.956 and 132.47 +/- 7.90 muM, respectively, with a concomitant down regulation of phosphorylated ERK1/2 but did not bind to receptor-2. Compound 1 was less hydrophobic than compound 2 and this may contribute to its increased activity. Compound 1 is a new addition to the small number of inhibitors of fibroblast growth factor-2-induced angiogenesis. The compound was a specific inhibitor in that it had no effect on vascular endothelial growth factor or epithelial growth factor-induced angiogenesis. Since angiogenesis is essential for tumour development we conclude that these compounds may have potential as anti-tumour agents.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Fibroblast Growth Factor 2/antagonists & inhibitors , Fibroblast Growth Factor 2/pharmacology , Neovascularization, Physiologic/drug effects , Sesterterpenes/pharmacology , Animals , Cattle , Cell Movement/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Chick Embryo , Drug Evaluation, Preclinical , Endothelial Cells/drug effects , Endothelial Cells/physiology , Fibroblast Growth Factor 2/metabolism , Humans , Models, Biological , Protein Binding , Receptor, Fibroblast Growth Factor, Type 2/metabolism , Sesterterpenes/metabolism , Wound Healing/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...